TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05497024

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Participants will discuss background, such as race, education, and living situation.~Participants will discuss Prostate cancer Participants will discuss feedback on the educational material

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Participants may answer questions that are sensitive in nature.
Study: NCT05309226

Intervention type: OTHER
Intervention: Cannabis use in pregnancy or cannabis exposure in utero
Description: Cannabis-related product use in pregnancy. Cannabis-related products will include all forms (e.g., dry flower, edibles, extracts, etc.) and formats of consumption (e.g., joint, bong, capsule, tincture, etc.).

Intervention type: OTHER
Intervention: Cannabis use in pregnancy or cannabis exposure in utero
Description: Cannabis-related product use in pregnancy. Cannabis-related products will include all forms (e.g., dry flower, edibles, extracts, etc.) and formats of consumption (e.g., joint, bong, capsule, tincture, etc.).
Study: NCT03894462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attempted Suicide Short Intervention Program
Description: ASSIP is a manualized, three-session intervention, delivered either in-person or via telehealth: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Zero Suicide Usual Care
Description: Participants will have access to outpatient treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged.
Study: NCT06640439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomodulation
Description: 830 nm LED was used to irradiate the post-extraction area

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antibiotic
Description: ibuprofen 0.3 g bid for 3 days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 days after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: ibuprofen 0.3 g bid for 3 days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 days after surgery
Study: NCT06645275

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: POCT test
Description: Patients undergo POCT testing on the day of warfarin administration, and based on the POCT results, the initial and maintenance doses of warfarin are determined according to the IWPC algorithm.
Study: NCT04728230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo consolidative thoracic radiation therapy
Study: NCT06496477

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ayo wearable
Description: Primary study device - the Ayo wearable which are glasses that emit either bright blue-spectrum white light or dim blue-spectrum white light or Mini motion logger AAM-32 - an actigraphy device work during the first and last week of the study on the participants wrist throughout most of the day, measuring activity. This will be used as an indicator of sleep.
Study: NCT05567315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anaesthetic injection
Description: Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hypnosis with Virtual reality mask
Description: A 20-minute virtual reality hypnosis session is performed from the time the patient is placed on the surgical table until the end of the oocyte poncture
Study: NCT04997278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coordinated Reset spinal cord stimulation
Description: Abnormal neuronal synchrony in terms of enhanced 4-9 Hz theta oscillations in EEG/MEG recordings appears to be an important pathophysiological finding in patients with neurogenic pain. To specifically counteract abnormal neuronal synchrony, we here set out to perform Coordinated Reset (CR)-Spinal Cord Stimulation (SCS). CR stimulation (Tass, 2003) aims at an anti-kindling, i.e. an unlearning or resetting of abnormal neuronal synchrony and abnormal synaptic connectivity, and, hence, long-lasting, sustained therapeutic effects that persist following cessation of stimulation (Tass \& Majtanik, 2006).
Study: NCT05936437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subjects treated with Newest medical device
Description: Newest is a sterile, non-pyrogenic, viscoelastic gel for single use for intradermal infiltrations. Newest is a medical device containing 2ml of the original association of polynucleotides (10mg/ml) and hyaluronic acid (10mg/ml).~Total number of treatments will consist in 4 Newest administrations: at T0 - basal, at T1- 2 weeks, at T2 - 4 weeks, at T3- 6 weeks.
Study: NCT04979143

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Approach
Description: The surgical laser used will be randomized. All lasers used during this trial are all FDA approved devices and used per routine clinical care.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Approach
Description: The surgical laser used will be randomized. All lasers used during this trial are all FDA approved devices and used per routine clinical care.
Study: NCT06147245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred culturally sensitive course of treatment
Description: 12-month person-centred and culturally sensitive intervention: Participants will attend 6 visits at SDCC including visits with a diabetes nurse, physician and dietitian. The course of treatment is focusing on extended time in consultations, use of technology for diabetes monitoring, meeting the same healthcare professionals, awareness of language barriers and use of accurate communication and dialogue tools in participants native language.
Study: NCT05901038

Intervention type: DEVICE
Intervention: Wearing heart rate monitors
Description: Participants will use 2 consumer wearable heart rate monitors: Polar H10 chest strap and Fitbit Inspire 2 fitness tracker.

Intervention type: DEVICE
Intervention: Wearing heart rate monitors
Description: Participants will use 2 consumer wearable heart rate monitors: Polar H10 chest strap and Fitbit Inspire 2 fitness tracker.

Intervention type: DEVICE
Intervention: Wearing heart rate monitors
Description: Participants will use 2 consumer wearable heart rate monitors: Polar H10 chest strap and Fitbit Inspire 2 fitness tracker.
Study: NCT05884073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit-based Resistance Training
Description: Participants will engage in a 12-week circuit-based resistance training program 2-3 times/week. Each supervised session will last about 30 minutes and will consist of 5 resistance exercises. Each exercise will be completed for 1 minute for a total of 5 minutes followed by a 1-minute rest. The circuit will then repeated 3 additional times (total of 4 circuits). All resistance sessions will be supervised by a certified fitness professionals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nature-based Walking
Description: Participants will be asked to engage in 30 minutes of self-paced walking in nature 2-3 days/week. Participants will be provided with a list of resources that direct them to walkable nature/green spaces close to their home or workplace.
Study: NCT05289544

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phone-Based Walk With Ease
Description: 6 week phone-delivered Walk With Ease Program
Study: NCT05780450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Therapy (tDCS)
Description: Transcranial direct therapy (tDCS) is a non-invasive neuromodulation therapy of the cerebral cortex, which consists of the application of electrical microcurrents, of approximately 2mA, through surface electrodes placed on the scalp. Transcranial therapy (tDCS) produces immediate effects on the ability of neurons to change their electrical potential.~Each session lasts between 20 and 30 minutes, and approximately 10 consecutive sessions should be performed. It will be applied through two surface electrodes of 25 to 35 cm2 at 2 mA.~The equipment has a European health certificate (CE), so it is an approved equipment that complies with all the safety measures for the application of the treatment.
Study: NCT05289544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-Based Walk With Ease
Description: 6 week phone-delivered Walk With Ease Program
Study: NCT05487391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706 injection
Description: QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vinorelbine Tartrate
Description: Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles
Study: NCT06205823

Intervention type: DRUG
Intervention: Immunotherapy
Description: Immunotherapy
Study: NCT06210204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth follow-up
Description: Patients to follow-up via phone after surgery
Study: NCT05276687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betadine
Description: Wound irrigation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: instillation in the wound
Study: NCT05201079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MBK-01
Description: A single dose of 4 capsules of MBK-01 (heterologous lyophilized fecal microbiota coming from healthy donors) orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dificlir
Description: Oral administration of 200mg/12 hours of fidaxomicin for 10 days.
Study: NCT05860387

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation improvement of early invasive aspergillosis
Description: Next generation improvement of early invasive aspergillosis test is intended to determine the suitability of new potential biomarkers of aspergillosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation improvement of early invasive aspergillosis
Description: Next generation improvement of early invasive aspergillosis test is intended to determine the suitability of new potential biomarkers of aspergillosis.
Study: NCT05736484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support Gamification
Description: Participants sign a pre-commitment contract agreeing to try their best to achieve their daily step goal. Over the 26-week intervention period, participants are endowed 70 points (10/day) weekly and informed they will lose 10 points each day goal is not met. Points are replenished at start of each week. At the end of each week, if the participant has 40 points or more, they will advance a level, or drop a level if they have less than 40 points. The levels include blue (lowest), bronze, silver, gold, platinum (highest). Participants select a family member or friend as a support partner to receive weekly email on participants' progress (points, game level, and average step count). Participants will also work with a virtual health coach by attending group sessions organized by them with other participants through video calls once a month to discuss ways to motivate participants to increase their physical activity.
Study: NCT05463406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The PLUS algorithm
Description: Combination of a clinical prediction score and LUS, and if needed PCT measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Management as usual
Study: NCT05034562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT or PET/MRI
Study: NCT04977674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Pre-treatment with naltrexone 45 min before the ketamine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Pre-treatment with naltrexone 45 min before the ketamine infusion.
Study: NCT05300451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab and hyaluronidase-fihj
Description: Daratumumab and hyaluronidase-fihj for subcutaneous (under the skin) injection has different dosing and administration instructions compared to daratumumab for intravenous (in the vein) infusion. Daratumumab and hyaluronidase-fihj contains recombinant hyaluronidase, which mimics hyaluronidase, a naturally occurring substance that increases permeability of subcutaneous tissue. This makes it possible for 15 mL containing 1,800 mg of daratumumab to be administered in approximately 3 to 5 minutes. Subjects will receive a 1800mg/30000u injection subcutaneously weekly for a total of 8 doses
Study: NCT04789850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: 200 mg oral for 360 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg oral for 360 days
Study: NCT05487391

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles
Study: NCT05108896

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3-Screenings Protocol
Description: The 3-Screenings Protocol is a modified bedside swallow exam (BSE) consisting of a study developed five-item decision tree algorithm including voice quality assessment and a 2-ounce water consistency assessment, the Yale Swallow Test, with a scored 3-ounce Water Swallow Test (3-WST), and the Toronto Bedside Swallowing Screening Test (TOR-BSST).
Study: NCT05487391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles
Study: NCT04977674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pre-treatment with placebo 45 min before the ketamine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pre-treatment with placebo 45 min before the ketamine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.
Study: NCT04651985

Intervention type: OTHER
Intervention: Eccentric strengthening exercises of the Achilles tendon
Description: This exercise will require the completion of slow active eccentric plantar flexion exercises with the forefoot positioned over the edge of a step. These exercises will be repeated twice daily (three sets of 15 repetitions with the knee in extension and three sets of 15 repetitions with the knee in flexion) during a three-month period. The amount of loading will be calibrated and progressed on a weekly basis by the physiotherapist according the participant's perceived effort and pain intensity.

Intervention type: OTHER
Intervention: Eccentric strengthening exercises of the Achilles tendon
Description: This exercise will require the completion of slow active eccentric plantar flexion exercises with the forefoot positioned over the edge of a step. These exercises will be repeated twice daily (three sets of 15 repetitions with the knee in extension and three sets of 15 repetitions with the knee in flexion) during a three-month period. The amount of loading will be calibrated and progressed on a weekly basis by the physiotherapist according the participant's perceived effort and pain intensity.
Study: NCT06557928

Intervention type: OTHER
Intervention: measurement
Description: Measurement of multiple physiological indicators and psychological status and multi-omics study

Intervention type: OTHER
Intervention: measurement
Description: Measurement of multiple physiological indicators and psychological status and multi-omics study
Study: NCT05487391

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles
Study: NCT04958668

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative intensive care using volatile sedation
Description: Patients admitted after valve surgery are receiving intensive care using volatile sedative per anaesthetic conserving device. The subject of the study is medical and nursing time management..
Study: NCT04599829

Intervention type: DEVICE
Intervention: AnkleSTRONG100/500/900
Description: At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (3 device types: Ankle STRONG 100/500/900) totalling 90 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use an ankle support device.

Intervention type: DEVICE
Intervention: AnkleSTRONG100/500/900
Description: At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (3 device types: Ankle STRONG 100/500/900) totalling 90 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use an ankle support device.

Intervention type: DEVICE
Intervention: AnkleSTRONG100/500/900
Description: At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (3 device types: Ankle STRONG 100/500/900) totalling 90 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use an ankle support device.
Study: NCT04548037

Intervention type: OTHER
Intervention: PET-CT examination
Description: The subject is placed in supine position, the head immobilized in a headrest. The imaging sequence begins with a scout view (viewing angle 90 °, 120 kV, 20 mA), then an X-ray scan is performed for the attenuation correction (120 kV, 5 mAs per slice, pitch 0.531, collimation 40 mm , FOV 70) and diagnostic CT scan (120 kV, 100-250 mA: auto mA, pitch 0.531, 40 MM, DFOV 25, ASIR 60%, thickness 1.25 mm). Finally, the positron emission tomography is acquired: static in 3D mode for 15 minutes, 30 minutes after the injection of 18 FDG, the axial field of view is 25, the matrix in 256 x 256, OSEM reconstruction 6 iterations 24 subsets, attenuation correction, diffused, and PSF. Gaussian filter, cutoff frequency of 4. Obtaining forty-seven contiguous sections of 3.26 mm thick.
Study: NCT06232694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;
Description: Induction Phase Regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;
Description: Consolidation therapy after remission

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Description: Four cycles in total.Patients who meet the criteria for autologous stem cell transplantation (ASCT) during the treatment process can undergo ASCT.Patients who meet the transplantation criteria and have a suitable donor can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Study: NCT05108896

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FEES
Description: A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tracheal Ultrasound
Description: Ultrasound imaging of the trachea, measuring tracheal diameter and endotracheal tube (ETT) size ratio within 72 hours prior to extubation
Study: NCT05842850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction intervention
Description: The intervention consist of 4-weeks limiting daily food intake to a window of 8 hours (8am to 4pm) and water-fasting for the remaining hours of the day. Participants (LBW NAFLD individuals only) will be instructed to eat a balanced diet according to the current dietary guidelines reduced by 20% calories to ensure energy deficit.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention
Study: NCT05508776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020
Description: Film-coated tablet~Route of administration: Orally~50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020
Description: Film-coated tablet~Route of administration: Orally~50 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Tablet (may be film-coated depending on brand)~Route of administration: Orally~400 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet~Route of administration: Orally~No active ingredient